Structural motifs encoded by individual exons of the human neurokinin-1 receptor gene interact differentially with selective agonists and antagonists.
Three chimeric receptors were constructed by exchanging exons between human neurokinin NK1 and NK3 receptor genes. The N-terminal sequences of these chimeric receptors are encoded by exon 1, exon 1-2, or exon 1-3 of the NK1 receptor gene, whereas the remaining C-terminal sequences of these chimeric receptors are encoded by corresponding exons of the human NK3 receptor gene. Substance P bound with high affinities to all three chimeric receptors, suggesting that in addition to the common structures composed of conserved amino acid residues among neurokinin receptors, structural elements encoded by the first exon of the human NK1 receptor gene may also play an important role for substance P binding. On the contrary, potent NK1 antagonists L703,606 and SR140,333 did not show any detectable binding to these chimeric receptors. In accordance, sequences encoded by exon 4, and possibly exon 5, are likely to contain important structural motifs that may directly or indirectly influence the binding of these antagonists. Further comparison of the binding affinities of highly selective NK1 agonists, [Sar9, Met(O2)11] substance P, substance P methyl ester, and septide, revealed that each agonist may interact differently with the human NK1 receptor. These results show that the exon-exchanging technique can be a useful tool for studying structure-function relationships of receptors in which exon-intron junctions are fully conserved among receptor subtypes.
Tian
Y
Y
Department of Biotechnology, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.
Wu
L H
LH
Pu
Y
Y
Huang
C C
CC
Chung
F Z
FZ
D000595:Amino Acid Sequence; D003001:Cloning, Molecular; D005091:Exons / Q000502:physiology*; D006801:Humans; D007457:Iodine Radioisotopes / Q000494:pharmacology; D008969:Molecular Sequence Data; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology; D011485:Protein Binding / Q000502:physiology; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives; D011812:Quinuclidines / Q000494:pharmacology; D011869:Radioligand Assay; D018040:Receptors, Neurokinin-1 / Q000819:agonists / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D013237:Stereoisomerism; D013373:Substance P / Q000031:analogs & derivatives / Q000494:pharmacology
D007457:Iodine Radioisotopes; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments; D010716:Phosphatidylinositols; D010880:Piperidines; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; D011993:Recombinant Fusion Proteins; C062618:substance P, Sar(9)-Met(O2)(11)-; C076851:L 703606; C085215:SR 140333; D013373:Substance P; C033611:substance P, methyl ester-; C054725:septide; D011761:Pyrrolidonecarboxylic Acid